Welcome to Genmab

Engineering a
transformative tomorrow

As a leading international biotechnology company, we believe in the transformative power of science and technology. Science is not only our bedrock, it is our inspiration. We believe in improving the lives of patients with cancer by creating and developing innovative and differentiated antibody therapeutics that will transform the future of cancer treatment. We are Genmab.

Learn more


Transforming the future of cancer treatment

Cancer presents constant challenges in our society—from advancing drug development to fulfilling the unmet medical needs of patients. At Genmab, we have an appreciation for the power of the human immune system that gives us a unique perspective on how to respond and find solutions. That’s why we are focused on harnessing the immune system’s natural ability to fight against diseases to create therapeutics that have the potential to transform how cancer is treated.

See our products

Our Technology Platforms

Pioneering the next generation of antibody platforms

With an in-depth knowledge of antibody biology, we discover, develop and select the best possible antibody products. This relentless drive to innovate and advance the process of antibody discovery has led to our proprietary antibody technologies.

See our science at work


Positive Topline Results in Second Part of CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis

The second part of the Phase 3 CASSIOPEIA study, conducted by IFM in collaboration with HOVON and Janssen, of daratumumab as maintenance treatment for patients with newly diagnosed multiple myeloma eligible for ASCT met the primary endpoint of progression-free survival at  pre-planned interim analysis.

Read the Company Announcement

We turn science into medicine. We use our deep antibody expertise to create cancer therapeutics with the potential to improve patients’ lives.

Load more

Genmab’s First Nine Months 2020 Financial Results

Genmab has published its financial results for the first nine months of 2020.

Read more

Join our mission to transform the future of cancer treatment.

Learn about career opportunities

You are now leaving Genmab.com to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.